Esophageal Carcinoma (ESCA) is a common and lethal malignant tumor worldwide. A role for mitochondria in tumorigenesis and progression has been proposed. The mitochondrial biomarkers were useful in nding signi cant prognostic gene modules associated with ESCA. In the present work, we obtained the transcriptome expression pro les and corresponding clinical information of ESCA from The Cancer Genome Atlas (TCGA). Differential expressed genes (DEGs) were overlapped with mitochondria related genes to obtain mitochondria related DEGs. The univariate cox regression, Least Absolute Shrinkage and Selection Operator (LASSO) regression, and multivariate cox regression was sequentially used to de ne the risk scoring model for mitochondria-related DEGs, and its prognostic value was veri ed in the external datasets GSE53624. Based on risk score, ESCA patients were divided into high and low risk groups. GO, KEGG and Gene Set Enrichment Analysis (GSEA) were performed to further investigate the difference between low and high risk groups in the gene pathway level. CIBERSORT was used to evaluate immune cell in ltration. The mutation difference between high and low risk groups was compared by the R package "Maftools". Cellminer was used to assess the interactions of the risk scoring model and drug sensitivity. As the most important outcome of the study, we obtained 306 mitochondria related DEGs, and constructed a 6-gene risk scoring model (APOOL, HIGD1A, MAOB, BCAP31, SLC44A2 and CHPT1). Between high and low risk group, pathways including "hippo signaling pathway" and "cell-cell junction" was enriched. According to CIBERSORT, samples with high risk demonstrated higher abundance of CD4 + T cells, NK cells, M0 and M2 Macrophages, and lower abundance of M1 Macrophages. The immune cell marker genes were correlated with risk score. In mutation analysis, the mutation rate of TP53 was signi cantly different between the high and low risk groups. Drugs with strong correlation with model genes and risk score were selected. In conclusion, we focused on the role of mitochondria-related genes in cancer development, and proposed a prognostic signature for individualized integrative assessment.
Esophageal Carcinoma (ESCA) is a common and lethal malignant tumor worldwide. A role for mitochondria in tumorigenesis and progression has been proposed. The mitochondrial biomarkers were useful in finding significant prognostic gene modules associated with ESCA. In the present work, we obtained the transcriptome expression profiles and corresponding clinical information of ESCA from The Cancer Genome Atlas (TCGA). Differential expressed genes (DEGs) were overlapped with mitochondria related genes to obtain mitochondria related DEGs. The univariate cox regression, Least Absolute Shrinkage and Selection Operator (LASSO) regression, and multivariate cox regression was sequentially used to define the risk scoring model for mitochondria-related DEGs, and its prognostic value was verified in the external datasets GSE53624. Based on risk score, ESCA patients were divided into high and low risk groups. GO, KEGG and Gene Set Enrichment Analysis (GSEA) were performed to further investigate the difference between low and high risk groups in the gene pathway level. CIBERSORT was used to evaluate immune cell infiltration. The mutation difference between high and low risk groups was compared by the R package “Maftools”. Cellminer was used to assess the interactions of the risk scoring model and drug sensitivity. As the most important outcome of the study, we obtained 306 mitochondria related DEGs, and constructed a 6-gene risk scoring model (APOOL, HIGD1A, MAOB, BCAP31, SLC44A2 and CHPT1). Between high and low risk group, pathways including “hippo signaling pathway” and “cell-cell junction” was enriched. According to CIBERSORT, samples with high risk demonstrated higher abundance of CD4+ T cells, NK cells, M0 and M2 Macrophages, and lower abundance of M1 Macrophages. The immune cell marker genes were correlated with risk score. In mutation analysis, the mutation rate of TP53 was significantly different between the high and low risk groups. Drugs with strong correlation with model genes and risk score were selected. In conclusion, we focused on the role of mitochondria-related genes in cancer development, and proposed a prognostic signature for individualized integrative assessment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.